Journal Article Review Epublish
PubMed: 42094611 DOI: 10.7150/thno.129910
STK17A (DRAK1) at the crossroads of apoptosis, immunity, and cancer: Emerging roles and therapeutic opportunities.
Theranostics 16(11):5830-5855
Authors: Leticia Christina Pires Gonçalves, Olivia Rastoin, Vira Morozova, Clément Buzet, Audrey Bennetot, Gilles Pagès, Cyril Ronco, Maeva Dufies
Affiliations
- Roca Therapeutics, Nice, France.
- University Côte d'Azur, Institut de Chimie de Nice (ICN), CNRS UMR 7272, Nice, France. V. N. Karazin Kharkiv National University, School of Chemistry, Kharkiv, Ukraine.
- Roca Therapeutics, Nice, France. University Côte d'Azur, Institut de Chimie de Nice (ICN), CNRS UMR 7272, Nice, France.
- University Côte d'Azur, Institute for Research on Cancer and Aging of Nice (IRCAN), CNRS UMR 7284, INSERM U1081, Nice, France.
- University Côte d'Azur, Institut de Chimie de Nice (ICN), CNRS UMR 7272, Nice, France.
- Institut Universitaire de France (IUF), Paris, France.
Abstract
Death-associated protein kinase-Related Apoptosis-inducing protein Kinase 1 (DRAK1/STK17A) is a serine/threonine kinase of the Death Associated Protein Kinase (DAPK) family. STK17A is widely expressed and enriched in immune tissues, and is primarily localized in the nucleus, though it can translocate to the cytoplasm in response to specific stimuli. STK17A stimulates apoptosis and cytoskeletal dynamics, but its physiological roles remain incompletely defined, in part due to limited availability of potent/selective chemical probes and the absence of STK17A in commonly used rodent models. In this review, we summarize current knowledge on STK17A, including its structure, evolution, expression patterns, molecular interactions, and roles in cancer as well as in autoimmune, cardiovascular, infectious, and neurological disorders. We also compare STK17A with its closest homolog, STK17B, highlighting both shared features and functional distinctions. The review further examines recent medicinal chemistry efforts that have yielded the first small-molecule modulators of STK17A (DRAK1) and STK17B (DRAK2), including dual inhibitors and emerging selective scaffolds. These compounds can serve as valuable chemical probes and hold promising therapeutic potential. Nonetheless, challenges of selectivity and functional validation remain, emphasizing the need for continued medicinal chemistry efforts to unlock the full potential of STK17A as a therapeutic target across cancer, autoimmune, and neurodegenerative diseases.
MeSH
Nanomedicine, Chemistry, Pharmaceutical, Neoplasms, Immunity, Therapeutics, Apoptosis, Physical Exertion, Protein Serine-Threonine Kinases